Supresen (Old Age Suppressor)
It is a key to rejuvenating your body and preventing diseases and disorders associated with senescent cells. Senescent cells accumulate in tissues and organs after people get older and develop age-related pathologies.
The presence of senescent cells determines the decline in health associated with aging.
Supresen is a medication for preventing aging, rejuvenating your body, and treating diseases associated with aging. It implies administering 3 senolytic agents (further referred to as SAs) – substances that inhibit dysfunctional or damaged cells.
Senolytic agents (SAs) suppress anti-apoptotic proteins that interfere with the programmed death of senescent cells and their replacement by healthy and young cells.
Apart from rejuvenation, there is a long list of diseases or disorders associated with accumulating senescent cells. These are:
- Cardiovascular diseases (treatment and prevention) – atherosclerosis, angina pectoris, arrhythmia, cardiomyopathy, congestive heart failure, coronary insufficiency, carotid artery disease, aortic disorders, endocarditis, coronary artery thrombosis, myocardial infarction, stroke and its prevention, hypertension, aortic aneurysm, diastolic heart failure, hypercholesterolemia, hyperlipidemia, mitral valve prolapse, peripheral vascular disease, impaired stress resistance of the cardiovascular system, myocardial fibrosis, and cerebral aneurysm.
- Inflammatory or autoimmune diseases – osteoarthritis, osteoporosis, oral mucosal disease, inflammatory bowel disease, kyphosis, and herniated disc.
- Neurodegenerative diseases – Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, dementia, mental impairment, memory and attention deficits, and motor neuron disease.
- Metabolic diseases – diabetes, diabetic ulcer, diabetic foot disease (treatment and prevention), metabolic syndrome, and obesity.
- Pulmonary diseases – pulmonary fibrosis, chronic obstructive pulmonary disease (further referred to as COPD), asthma, cystic fibrosis, emphysema, bronchiectasis, and decreased lung function caused by aging.
- Prevention and treatment of eye diseases associated with aging: macular degeneration, glaucoma, cataracts, age-related farsightedness, and vision loss.
- Prevention and treatment of disorders caused by aging – kidney disease, renal failure, frailty syndrome, hearing loss, muscle fatigue, skin disorders, skin lesions, liver fibrosis, pancreatic fibrosis, oral submucous fibrosis, and sarcopenia.
- Prevention and treatment of dermatological disorders – wrinkles, eczema, psoriasis, hyperpigmentation, nevus, fleeting rash, atopic dermatitis, hives, photoaging, itchy skin, eosinophilic skin diseases, reactive neutrophilic dermatoses, pemphigus, pemphigoid, immunobullous diseases, the fibrocystic proliferation of epidermal cells, lymphomas, and cutaneous lupus erythematosus.
- Prevention and treatment of atherosclerosis, osteoarthritis, pulmonary fibrosis, hypertension, COPD, asthma, irritable bowel syndrome, Crohn’s disease, ulcerative colitis, herniated disc, reduced immunity, female reproductive system diseases, obesity, etc.
Senescent cells are senescent preadipocytes, senescent endothelial cells, senescent fibroblasts, senescent neurons, senescent epithelial cells, senescent mesenchymal cells, senescent smooth muscle cells, senescent macrophages, senescent chondrocytes, which should be removed and replaced with young, healthy cells.
You can achieve that by administering a combination of 3 senolytic agents (SAs) presented in Supresen. SAs lead to the death and replacement of at least 25% of senescent cells (SCs) in an organ or tissue containing SCs associated with a disease or disorder caused by aging.
In treating osteoarthritis, SAs lead to the death of SCs in the affected joint. SAs induce collagen formation, inhibit the erosion of the proteoglycan layer, and inhibit bone erosion in the joint.
In treating and preventing lung diseases or disorders associated with aging, SAs selectively lead to the death of SCs and their replacement by healthy cells. It is needed to treat pulmonary fibrosis, COPD, decreased lung function, cystic fibrosis, emphysema, bronchiectasis, and asthma.
SAs increase the stability of atherosclerotic plaque, reduce the lipid content in the plaque located in the blood vessel, and inhibit the formation of new atherosclerotic plaques in blood vessels. The use of Supresen is vital for the treatment and prevention of a disease or disorder caused by atherosclerosis – angina pectoris, myocardial infarction, arrhythmia, stroke, cardiomyopathy, congestive heart failure, endocarditis, carotid artery thrombosis, aortic aneurysm, hypertension, hypercholesterolemia, coronary artery thrombosis, hyperlipidemia, mitral valve prolapse, peripheral vascular disease, impaired stress resistance of the cardiovascular system, myocardial fibrosis, cerebral aneurysm, aortic disorders, carotid artery disease, and coronary artery disease. SAs inhibit the formation and reduce the number of atherosclerotic plaques in blood vessels.
SAs used in Supresen prevent eye diseases or disorders associated with aging – visual impairment, glaucoma, macular degeneration, cataracts, and vision loss.
SAs are vital in treating kidney disease, renal failure, frailty, hearing loss, muscle fatigue, skin disorders, skin lesions, liver fibrosis, pancreatic fibrosis, oral submucous fibrosis, and sarcopenia.
Oncopathology uses SAs between courses of chemotherapy and radiation therapy. SAs prevent cancer and inhibit metastasis in melanoma, prostate cancer, testicular cancer, breast cancer, brain cancer, pancreatic cancer, colon cancer, small intestine cancer, thyroid cancer, gastric cancer, lung cancer, ovarian cancer, Kaposi sarcoma, skin cancer, renal cell cancer, head and neck cancer, throat cancer, squamous cell carcinoma, bladder cancer, osteosarcoma, cervical cancer, endometrial cancer, esophageal cancer, liver cancer, and kidney cancer.
A decreasing number of SCs in the body leads to an improvement in the physical functions of the whole body, a decreasing number of atherosclerotic plaques, a decreasing amount of damaged lung tissue, improving the cardiovascular system, a decreasing number of neurological diseases or disorders, a decreasing number of side effects from chemo- and radiation therapy, and other issues associated with aging.
SAs affect only SCs ready for apoptosis; they do not affect ageless cells. There is also an increase in ageless cells in an organ or tissue. SAs reduce the number of cells with damaged DNA. SAs reduce the production rate of beta-galactosidase associated with aging.
SAs reduce the level of proteins associated with aging (p21, p16, and IL-1a). SAs reduce the level of anti-apoptotic proteins that interfere with the renewal of all tissues.
SAs stimulate the production of collagen in damaged joints, which contributes to the restoration of joint functions.
SAs stimulate the production of collagen in the skin, which removes wrinkles.
SAs lower the level of lipids in the blood plasma, reduce the level of total cholesterol, and reduce the level of aging markers in the arteries, including the aortic arch.
SAs reduce body fat mass.
SAs increase the elasticity of the lungs.
Aging is a risk factor for most chronic diseases, disability, and poor health. SCs accumulate with age and contribute partially or significantly to cell and tissue deterioration underlying aging and age-related diseases. Cells can also become senescent after exposure to climatic, chemical, physical, and biological factors or health disorders. Supresen contains agents for the selective elimination of SCs. They are associated with numerous pathologies and diseases, such as aging-associated pathologies and diseases. Cell aging-associated diseases or disorders can be treated or prevented by the administration of senolytic agents (SAs); cell aging-associated diseases being treated or prevented include cardiovascular, inflammatory, pulmonary, neurological, and dermatological diseases and disorders, side effects from chemo- and radiation therapy, metastasis prevention, metabolic syndrome, musculoskeletal system diseases, lung diseases, bronchial diseases, atherosclerosis, diabetes, etc.
SAs presented in Supresen are sufficient to destroy a significant amount of SCs and replace them with young, healthy cells. SAs used in Supresen selectively destroy and remove SAs and facilitate their selective destruction. SAs do not destroy the ageless cell. The mechanism by which CAs induce programmed cell death (apoptosis) is that CAs block pathological anti-apoptotic proteins. At the same time, they do not affect the normal cells and replace the removed SCs.
SAs are small organic molecules that are inhibitors of anti-apoptotic proteins. SAs connect growth factors and signaling pathways in response to DNA damage and mediate proteasomal degradation in the nucleus. Supresen includes 3 SAs. This combination leads to a significant increase in the death of senescent cells compared with using each SA separately. The effect of 3 SAs used in Supresen becomes synergistic.
SAs used in Supresen affect most SCs in combination. These are aging preadipocytes, aging endothelial cells, aging fibroblasts, aging neurons, aging epithelial cells, aging mesenchymal cells, aging smooth muscle cells, aging macrophages (cells of the immune system), aging chondrocytes, etc.
The mass of molecules secreted by SCs when the removal of these cells is ineffective negatively affects and damages the surrounding healthy cells and tissues, thus causing an inflammatory phenotype of the senescent cell.
Thus, SAs presented in Supresen selectively destroy senescent preadipocytes and may be suitable for treating and preventing diabetes type 1 and type 2, metabolic syndrome, and obesity. SAs can selectively destroy senescent endothelial cells, smooth muscle cells, and macrophages. It makes Supresen suitable for the treatment of cardiovascular diseases, including atherosclerosis. It also contributes to the renewal and rejuvenation of the immune system. SAs selectively destroy aging fibroblasts, thus rejuvenating the skin, blood vessels, and all organs and tissues with connective tissue. Senolytic agents (SAs) provide the neuroprotective effect of Supresen, improve the functional activity of the central and peripheral nervous system, increase IQ, improve memory, cope with depression, normalize sleep and wakefulness, etc.
SAs can selectively destroy senescent cells (SCs) of the retina, thus allowing using Supresen for preventing and treating eye diseases, including macular degeneration and vision loss.
Selective death of epithelial cells (for example, senescent lung or kidney epithelial cells) may be vital in treating and preventing kidney and lung diseases (such as chronic obstructive pulmonary disease or pulmonary fibrosis).
SAs can selectively destroy senescent immune cells (for example, macrophages). Thus, Supresen has pronounced immunoprotective properties.
SAs can selectively destroy aging chondrocytes, thus allowing using Supresen for treating and preventing musculoskeletal system diseases (for example, osteoarthritis, arthritis, arthrosis, osteochondrosis, spinal disorders, spondyloarthritis, etc.).
A characteristic sign of cell aging is the gradual loss of function or degeneration at the molecular, cellular, tissue, and organism levels. Aging-associated diseases and disorders include cardiovascular, inflammatory, immune, autoimmune, pulmonary, eye, metabolic, neurological (neurodegenerative diseases), age-related diseases and disorders (caused by aging), skin conditions, dermatological diseases, etc.
Aging-related degeneration leads to pathologies such as sarcopenia, atherosclerosis, heart failure, osteoporosis, lung failure, kidney failure, neurodegeneration (including macular degeneration, Alzheimer’s disease, and Parkinson’s disease), and many other diseases. These are mental disorders, Alzheimer’s disease and dementia, Huntington’s disease, cardiovascular diseases (atherosclerosis, diastolic heart dysfunction, aneurysms, including aortic aneurysm, angina pectoris, arrhythmias, cardiomyopathy, congestive heart failure, coronary artery disease, myocardial infarction, endocarditis, endarteritis, hypertension, carotid artery disease, peripheral vascular disease, obliterating atherosclerosis, impaired stress resistance of the cardiovascular system, myocardial fibrosis); metabolic diseases and disorders (obesity, diabetes, metabolic syndrome, etc.); motor impairment and disorders (e.g. Parkinson’s disease, motor neuron disease, Huntington’s disease); cerebrovascular disease (e.g. cerebrovascular disease); emphysema, osteoarthritis, benign prostatic hyperplasia, pulmonary diseases (e.g. idiopathic pulmonary fibrosis, COPD, emphysema, obstructive bronchitis, asthma, etc.); inflammatory or autoimmune diseases and disorders (e.g. osteoarthritis, eczema, psoriasis, osteoporosis, mucositis); ophthalmic diseases (macular degeneration, cataracts, glaucoma, vision loss, age-related farsightedness); diabetic foot disease, diabetic ulcer, metastasis, side effects after chemotherapy and radiation therapy, aging-associated diseases and disorders (kyphosis, kidney failure, frailty, baldness, hearing loss, muscle fatigue, skin conditions, sarcopenia, and herniated disc); and other diseases and disorders caused by aging (resulting from exposure to radiation and chemical environmental factors, smoking, consumption of fatty and high sugar foods, and exposure to environmental factors); wound healing, nevus, and fibrotic diseases and disorders (cystic fibrosis, renal fibrosis, liver fibrosis, pulmonary fibrosis, fibrocystic mastopathy, oral submucous fibrosis, myocardial fibrosis, and pancreatic fibrosis).
SAs help prevent or treat osteoarthritis, osteoporosis, osteochondrosis, psoriasis, oral mucositis, rheumatoid arthritis, inflammatory bowel disease, eczema, kyphosis, herniated disc, chronic bronchitis, lung disease, COPD, and idiopathic pulmonary fibrosis.
Degenerative joint diseases imply the fluttering of cartilage in areas of severe mechanical wear, bone sclerosis, and thickening of the cartilage layer and joint capsule. The fluttering leads to the stratification of the superficial layers of cartilage. Collagen in cartilage becomes disorganized, and proteoglycans disappear from the cartilage surface. When there are no proteoglycans and their protective, lubricating effect, collagen fibers in the joint become susceptible to degradation, and mechanical destruction follows. Factors that cause joint and spinal diseases include increasing age, obesity, previous joint damage, joint overload, weak muscles, and genetics. These factors are a common cause of chronic disability in older people. Joint symptoms include sore or stiff joints, especially the hips, knees, and lower backs, and pain that may worsen towards the end of the day or after exercise. The neck, knuckles, and elbows may also be affected. By selectively destroying senescent cells (SCs), senolytic agents (SAs) inhibit the loss or erosion of proteoglycan layers in the joints and accelerate collagen production. Removal of SCs causes a decrease in the number of inflammatory cytokines, and inflammation and pain disappear. SAs used in Supresen can restore and increase the strength of the joint.
SAs presented in Supresen are vital for treating and preventing rheumatoid arthritis, kyphosis, and osteoporosis.
SAs can treat and prevent irritable bowel syndrome, ulcerative colitis, and Crohn’s disease.
SAs also help prevent and treat herniated discs.
Inflammatory and autoimmune diseases that can be treated or prevented with SAs include age wrinkles, eczema, psoriasis, osteoporosis, and lung diseases (COPD, pulmonary fibrosis, emphysema, bronchiectasis, asthma, and inflammatory bowel disease). SAs are essential for all smokers.
Using senolytic agents (SAs) can also treat and prevent organ fibrosis – kidney, liver, pancreatic, cardiac, and oral submucous fibrosis.
Neurological diseases and disorders (prevention and treatment) include aging-associated diseases, Parkinson’s disease, Alzheimer’s disease (and other types of dementia), motor neuron disease, mental disorders, and Huntington’s disease.
SAs used in Supresen are vital for treating and preventing eye diseases (age-related macular degeneration, glaucoma, vision loss, myopia, age-related farsightedness, cataracts, and clouding of the eye chambers). SAs normalize metabolic processes in the eye tissues and prevent the development and progression of ophthalmic diseases.
SAs are effective for treating and preventing metabolic disorders. These are diabetes, metabolic syndrome, diabetic foot disease, diabetic ulcers, and obesity. The death of senescent preadipocytes promoted by SAs provides a clinical benefit to a person with diabetes, obesity, or metabolic syndrome.
SAs are vital for treating and preventing kidney failure.
SAs may help treat and prevent dermatological diseases: psoriasis, eczema, age wrinkles, pruritis, dysesthesia, erythroderma, lichen planus, lichenoid dermatitis, atopic dermatitis, eosinophilic dermatitis, reactive neutrophilic dermatitis, pemphigus, pemphigoid, skin cell proliferation associated with aging, cutaneous lymphomas, and cutaneous lupus erythematosus.
SAs are vital for treating or preventing metastasis in oncopathology. SAs can also inhibit the proliferation of tumor cells. When SAs destroy senescent cells (SCs), they inhibit tumor development. Using SAs between cycles can attenuate toxic side effects caused by chemo- and radiation therapy. Destruction of SCs by SAs in a patient increases sensitivity to chemotherapy and radiotherapy.
SAs contribute to delaying the development and arrest of age-related diseases or disorders. SA blocks the factors that cause aging. Age-related diseases or disorders include kidney failure, kyphosis, herniated disc, weakness, baldness, hearing loss, visual acuity loss, muscle fatigue, skin conditions, skin nevus, diabetes, metabolic syndrome, and sarcopenia. Age-related diseases or disorders also include dermatological (skin) conditions: the presence of wrinkles, including superficial fine lines, hyperpigmentation, scars, keloid scars, dermatitis, psoriasis, eczema (including seborrheic eczema), acne rosacea, vitiligo, ichthyosis vulgaris, dermatomyositis, and solar keratosis.
SAs inhibit the aging of adult stem cells, prevent their death, and facilitate the removal of adult stem cells that have become senescent. SAs are vital for preventing the aging of stem cells and maintaining tissue regenerative capacity at a young level.
SAs provide prolonged survival compared to the expected survival if a person does not receive SAs, which selectively remove senescent cells (SCs). Individuals needing SAs include those who already have or are at risk of developing the disease or disorder described above and those who need to prevent it. A person may have a genetic predisposition to a condition that would benefit from using SAs and SCs removal.
SAs can selectively destroy several types of SCs – aging preadipocytes (adipose tissue cells), aging endothelial cells (vascular cells), aging fibroblasts (skin, joint, and connective tissue cells), aging neurons, aging epithelial cells (skin, intestines, lungs, vessels, etc.), aging mesenchymal cells (internal organs), aging smooth muscle cells (vessels, internal organs, etc.), aging macrophages (immunity), and aging chondrocytes (musculoskeletal system).
SAs feature selectivity, thus contributing to the physiological destruction of only senescent cells.
The number of SCs accumulates with age. This process causes aging and development (exacerbation) of diseases of brain tissues, tissues and parts of the eye, lung tissues, heart tissues, blood vessels, joints, bones, skin, muscles, and other tissues and organs. Selective removal of at least 20% of SCs from tissues and organs can lead to a significant therapeutic effect in almost any disease and rejuvenation.
When treating a cardiovascular or atherosclerosis-associated disorder, SAs cause at least 25% of the SCs in the arterial plaque to die, thereby shrinking it and stopping its growth.
When treating musculoskeletal system disease, SAs remove 20-25% of the SCs and replace them with young cells.
When treating lung disease, SAs cause death and replacement of at least 20% of SCs.
SAs increase the amount of collagen produced in the skin. This fact ensures the effectiveness of SAs against wrinkles.
Using SAs in atherosclerosis-associated cardiovascular diseases leads to a statistically significant decrease in vascular plaques and a decrease in the number of SCs in the arteries.
The number of aging and damaged cells in the lungs of a smoker decreases, and the external respiration functions improve.
Pharmaceutical formulations of Supresen contain a combination of 3 SAs –inhibitors of several members of the anti-apoptotic protein family, Bcl-2, which inhibit at least Bcl-xL, Bcl-2/Bcl-xL/Bcl-w, Bcl-2/Bcl-xL, or Bcl- xL/Bcl-w.
From laboratory data:
Senolytic agents (SA) remove senescent cells (SC) with an established SASP phenotype (phenotype associated with aging). SAs destroy SCs with increased DNA damage response.
SAs remove SCs and give rise to young cells of various cell types (the versatility of Supresen).
SAs remove senescent primary lung fibroblasts.
SAs remove damaged and aging cells (SCs) from the respiratory system, incl. in smokers.
SAs remove SCs with increased DNA damage response.
SAs cause the death of SCs through apoptosis.
SAs induce the death of damaged, senescent cells by inhibiting the anti-apoptotic protein Bcl-xL (a member of the Bcl-2 anti-apoptotic protein family).
SAs remove the SCs of the musculoskeletal system.
SAs remove the SCs of vessels affected by atherosclerosis, reducing its symptoms. SCs removal maintains resistance to cardio stress during aging.
SAs block side effects and improve the quality of chemotherapy and radiation therapy, reducing their aging-enhancing impact.
SAs block metabolic pathways associated with aging.
Supresen goes well with other medicines, dietary supplements, and cosmetics.
Dosage form: for internal or external use. Byproducts: excreted in the urine.